Arthur Klausner discusses liquidation and participating preferred stock in the third part of his series on VC term sheets.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Deal Snapshot: Hengrui makes its third potential billion-dollar licensing deal of 2025, this time sending rights to Phase III hypertrophic cardiomyopathy drug HRS-1893 to Braveheart.
The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.
Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.
R&D leaders highlighted two potential first-in-class assets during a therapeutic area overview, but regulatory filings remain years out.
The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.
Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.
R&D leaders highlighted two potential first-in-class assets during a therapeutic area overview, but regulatory filings remain years out.
